Search NLS News

Abera Bioscience has been awarded a grant from Vinnova to advance the development of its pneumococcal vaccine, Ab-01.12, towards clinical trials.

Scientists at deCODE genetics have discovered rare sequence variants, predicted to cause a loss of function of ITSN1, that are associated with a high risk of Parkinson‘s Disease.

The transaction is valued at approximately USD 2.6 billion equity value and USD 2.5 billion net of cash, on a fully diluted basis.

Sweden boasts a global reputation for cutting-edge research and innovation, but the country's ambition to maintain its leading position as an innovation nation faces a significant challenge: securing and retaining top talent from abroad. Why then is the route to work permits for international professionals complex and lengthy?

When InDex Pharmaceuticals announced earlier this year that it would discontinue all development of the company’s drug candidate, Flerie Invest saw an opportunity to become listed and offer new shareholders access to and liquidity in biotech companies while retaining its long-term, active investment strategy.

Besides her technical knowledge in clinical development and clinical operations, leading and managing company and regulatory agencies’ teams has been a core aspect of Margrethe Sørgaard’s career path.

BerGenBio has announced that CEO, Martin Olin will be leaving the company to pursue other opportunities.

Sofia Mayans, who transitioned from her research to co-founding InfiCure Bio, is taking on a new role as Director of Business Development at Diamyd Medical in Umeå.

The capital of Sweden possesses not only world-renowned academic research and high profile life science companies, it is also home to many of the country’s most important national life science efforts and leading centers.

The participating investors are existing shareholder Invus, as well as one or more funds under the management of Capital Group, a new investor in Vicore.